Features of endothelial dysfunction in early diabetic nephropathy.
about
Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)Two-week treatment with pravastatin improves ventriculo-vascular haemodynamic interactions in young men with type 1 diabetes.Microalbuminuria in systemic sclerosisDyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.Endothelial dysfunction in diabetes: pathogenesis, significance, and treatment.Postprandial hyperglycaemia: potential relationship to the development and progression of diabetic nephropathy.Blood pressure and cardiac autonomic function in relation to risk factors and treatment perspectives in Type 1 diabetes.ACE inhibitor intervention in Type 1 diabetes with low grade microalbuminuria.Serum Lp(a) lipoprotein concentrations in insulin dependent diabetic patients with microalbuminuriaClearance of plasminogen activator--a major determinant of plasma concentration: therapeutic and diagnostic implications.Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective.eNOS deficiency predisposes podocytes to injury in diabetes.von Willebrand factor, endothelial dysfunction, and cardiovascular disease.Cohort study of predictive value of urinary albumin excretion for atherosclerotic vascular disease in patients with insulin dependent diabetes.Coronary heart disease in diabetes mellitus--antecedents and associationsAssessment of carotid atherosclerosis in type 2 diabetes mellitus patients with microalbuminuria by high-frequency ultrasonography.Therapeutic regulation of endothelial dysfunction in type 2 diabetes mellitus.Usefulness of microalbuminuria versus the metabolic syndrome as a predictor of cardiovascular disease in women and men>40 years of age (from the Rancho Bernardo Study).Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptorsPlasma gelsolin and circulating actin correlate with hemodialysis mortality.Early Clinical Implications of Microalbuminuria in Patients with Acute Ischaemic Stroke.Proinsulin C-peptide: friend or foe in the development of diabetes-associated complications?Strategies to reverse endothelial dysfunction in diabetic nephropathyEndothelial dysfunction as a potential contributor in diabetic nephropathy.Increased albumin excretion in diabetes.Microvascular dysfunction: an emerging pathway in the pathogenesis of obesity-related insulin resistance.Uncoupling of VEGF with endothelial NO as a potential mechanism for abnormal angiogenesis in the diabetic nephropathy.Influence of cardiac nerve status on cardiovascular regulation and cardioprotectionInhibition and stimulation of nitric oxide synthesis in the human forearm arterial bed of patients with insulin-dependent diabetesOxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction?The effects of endothelin-1 and NG-nitro-L-arginine methyl ester on regional haemodynamics in conscious rats with streptozotocin-induced diabetes mellitus.Impaired release of tissue plasminogen activator from the endothelium in Graves' disease - indicator of endothelial dysfunction and reduced fibrinolytic capacity.Decreased number of circulating endothelial progenitor cells in patients with Graves' hyperthyroidism.Spatial and temporal relationships between cadherins and PECAM-1 in cell-cell junctions of human endothelial cellsRenal and vascular benefits of C-peptide: Molecular mechanisms of C-peptide action.Microalbuminuria: pathogenesis, prognosis and management.Urinary albumin excretion is independently associated with C-reactive protein levels in overweight and obese nondiabetic premenopausal women.Homocysteine-lowering treatment with folic acid plus vitamin B6 lowers urinary albumin excretion but not plasma markers of endothelial function or C-reactive protein: further analysis of secondary end-points of a randomized clinical trial.Coagulation and fibrinolysis parameters in type 2 diabetic patients with and without diabetic vascular complications.Effects of lisinopril, irbesartan, and amlodipine on the thrombogenic variables in the early and late stages of the treatment in hypertensive patients.
P2860
Q24796737-FF0FB2BC-57D0-43B8-A76B-3D944D1F833DQ33283202-D0A57227-66AF-4938-8076-21D1D8D1FECBQ33564421-7ED422C9-E1DD-4E93-8AA7-BC189B62169CQ33776181-7D060DCF-70C2-4C08-AEAC-6F18D2D8E965Q33776230-D3B45385-DFE9-46E3-B151-68A91B5334DDQ34166411-30D31B0F-9BEA-4DF7-85D8-82C0F70B3BDDQ35065524-A6EF3874-C82A-4659-8173-58EDBE26E317Q35106214-2F37A42B-E24A-483B-84DC-50977E0C7CBEQ35180730-C9D1ACB3-774E-4180-96ED-D5D83AB612A3Q35224553-E3BD412E-40CA-4968-9B79-E4AF0CD788F9Q35648485-6605140C-8083-41B6-B5FB-1B7D21DA2266Q36352132-EB064D2F-2FB8-46C7-8A42-9F9FB3714F54Q36481209-83C58AB1-6CBF-4275-8DBE-E4E5DA62E52BQ36597794-0146CF51-4A1D-40B6-8844-D869CB3C559BQ36682356-2D19BD65-F411-4C9E-A8E2-7849C0CC1D8EQ36729116-FE70600C-2D1A-4FEB-8DCD-0D7762A53DCBQ36892489-7A839F0A-D1B2-4F2F-81FA-498D77AC49CBQ37011183-128B1681-0F3C-4A63-8160-5A886F2BCB7DQ37167494-9E9B36D0-0F26-4C07-A5CB-1D0568901EC8Q37182006-8CBEC609-57B5-41CE-B262-6CE4102880EDQ37353063-D9FF7BDD-482B-4704-B8A9-95F6495E29B8Q37428866-1B424EA9-11BD-4966-870A-60441B45E11AQ37557795-C7834E99-801A-48A4-9E9B-15FB9C86A136Q37806614-0112779B-503B-4E66-A5D3-C63B03FBFD0CQ37906391-34670ED8-4CD7-47D1-A606-9E134F294EEAQ38072622-CB3BB931-6CED-4CA5-B38C-65E6328F2A5CQ38175408-A45D5315-26CF-4C2D-937E-1D41EB24AD79Q39434028-89C49547-0415-4887-BB8E-84F81B135E48Q41022241-8F762243-AFB5-4D6E-B41B-E970B2397C23Q41740391-616B221C-3127-4359-B78D-A561B4E44B9EQ42242074-FBB53EFC-47C2-45CF-9192-7C602C7B24E4Q42466804-94E4004C-B8BD-405E-9136-C68A2F106F8CQ42473520-48F22D31-B8B1-48CB-838A-476763C17456Q42770764-194A336D-A503-4B13-AC00-1774CC21A37DQ43078102-852CA5CD-4727-4AEE-B308-6FD806F93DB9Q43900991-BF02DDE9-19E8-437B-B03E-46F574B180F1Q43922723-461AD4FF-958E-4D5E-BE34-721274D2C2E6Q44364949-70167130-4572-45BF-9E8C-96640792414AQ45193883-8453C164-0E8D-4015-939A-FFCEC15061A1Q46001140-375ED442-64D3-4AEE-B5B8-B00B9B346DCE
P2860
Features of endothelial dysfunction in early diabetic nephropathy.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Features of endothelial dysfunction in early diabetic nephropathy.
@en
Features of endothelial dysfunction in early diabetic nephropathy.
@nl
type
label
Features of endothelial dysfunction in early diabetic nephropathy.
@en
Features of endothelial dysfunction in early diabetic nephropathy.
@nl
prefLabel
Features of endothelial dysfunction in early diabetic nephropathy.
@en
Features of endothelial dysfunction in early diabetic nephropathy.
@nl
P2093
P1433
P1476
Features of endothelial dysfunction in early diabetic nephropathy.
@en
P2093
J Bjerre-Knudsen
P304
P356
10.1016/S0140-6736(89)91365-2
P407
P577
1989-03-01T00:00:00Z